Your browser doesn't support javascript.
loading
Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.
Lotfi, Malihe; Morshedi Rad, Dorsa; Mashhadi, Samaneh Sharif; Ashouri, Atefeh; Mojarrad, Majid; Mozaffari-Jovin, Sina; Farrokhi, Shima; Hashemi, Maryam; Lotfi, Marzieh; Ebrahimi Warkiani, Majid; Abbaszadegan, Mohammad Reza.
Afiliación
  • Lotfi M; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Morshedi Rad D; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mashhadi SS; Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ashouri A; School of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.
  • Mojarrad M; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mozaffari-Jovin S; Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Farrokhi S; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Hashemi M; Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Lotfi M; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ebrahimi Warkiani M; Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Abbaszadegan MR; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Stem Cell Rev Rep ; 19(8): 2576-2596, 2023 11.
Article en En | MEDLINE | ID: mdl-37723364
Rapid advancement in genome editing technologies has provided new promises for treating neoplasia, cardiovascular, neurodegenerative, and monogenic disorders. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has emerged as a powerful gene editing tool offering advantages, including high editing efficiency and low cost over the conventional approaches. Human pluripotent stem cells (hPSCs), with their great proliferation and differentiation potential into different cell types, have been exploited in stem cell-based therapy. The potential of hPSCs and the capabilities of CRISPR/Cas9 genome editing has been paradigm-shifting in medical genetics for over two decades. Since hPSCs are categorized as hard-to-transfect cells, there is a critical demand to develop an appropriate and effective approach for CRISPR/Cas9 delivery into these cells. This review focuses on various strategies for CRISPR/Cas9 delivery in stem cells.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Pluripotentes / Sistemas CRISPR-Cas Límite: Humans Idioma: En Revista: Stem Cell Rev Rep Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Pluripotentes / Sistemas CRISPR-Cas Límite: Humans Idioma: En Revista: Stem Cell Rev Rep Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos